gravis. Vikram, meratide progress and clinical in significant made positive In afternoon, of and therapies. data Since number or first-in-class II you, good Thank everyone. myasthenia the includes initiated broad advancing practice-changing UPLIZNA a study update, last potentially Phase with type we diabetes quarter, our pipeline, generalized III we of delivered a have X potentially which our best-in-class in Phase third
Additionally, the the this FDA in medicine. Breakthrough important for underscoring IgGX-related Therapy impact granted potential of designation UPLIZNA diseases
Phase also results from evaluating positive reporting medical studies rocatimlumab major at data in III from dermatitis. the IMDELLTRA, conferences, We programs AMG-XXX, and promising first oncology [indiscernible] X several of while showcased atopic including
Let's begin medicine. general with
unmet track II in XXXX. obesity, upon MariTide previously confident II and of obesity-related we diabetes. in remain top are forward chronic XX-week will Phase late important profile the medical seeing to weight study the mentioned, X and from needs in As a the of in line based MariTide address on interim Phase look ongoing analysis type conditions We differentiated MariTide data management, study are
broad planning diabetes. X actively and in to conditions expect are initiate Phase type obesity-related obesity, III and a We program
has This patients Phase monthly type with even in X MariTide quarter, be dedicated with potential we obesity. frequent this MariTide less initiated dosing. II trial to diabetes, or the a living first investigating setting with in without the and therapy
patients. MariTide, Beyond enrolling Phase actively is AMG-XXX I our of trial
incretin also and obesity preclinical programs, injectable mechanisms. oral which both approaches both include We to continue incretin our comprising advance and non
for IMDELLTRA, potentially LP medicine interfering cardiovascular DLLX in studies lines a to Also targeting small Phase fully targeting extensive literally or III with underway trial cell bispecific disease. advancing BITE first-in-class enrolled medicine. engager In of therapy both general lipid in oncology, cell T earlier stage is rapidly small RNA olpasiran, into best-in-class progress. Phase lung molecule, stage and cancer The olpasiran our continues outcomes X is III of
reduced subcutaneous [indiscernible] second experience, enhance line part program, Phase further patient Phase as small with and the extensive-stage a stage Phase To III the cell initiated we follow-up extensive cancer, lung impressive study in IMDELLTRA evaluating a and have of activity we safety monitoring are XXX we in our anticancer later of lung evaluating Delphi or II patients with Ib In September, sustained patients demonstrating cancer. small profile. data presented from cell study manageable protocols
which cancer. a X IMDELLTRA data efficacy We study and small cell cycles Delphi in Ib also platinum-based ongoing chemotherapy. maintenance chemotherapy to extensive-stage similar cell following lung from first-line lung XXX, PD-LX test cancer, combined inhibitor of inhibition is extensive-stage with design of XXX, PD-LX the and presented Phase inhibition versus Delphi alone, III following IMDELLTRA therapy the This study, PD-LX of as first-line Phase small our
median IMDELLTRA overall a follow-up of and With estimated XX%. manageable X.X X-month safety of of progression-free survival a duration of of profile, control median months disease XX months, survival has X.X demonstrated median a months,
from our announce post-taxane a evaluating initiate authorities, castrate-resistant in Moving exploration we dose The regulatory CDX first-in-class will III in Zaloritamig, metastatic Steep following recently by cancer, promise with quarter. in cohort study monotherapy with evidenced patients to X consultation pleased I was CRPC. bispecific Zaloritimig Phase presented molecule, or to data are prostate this of mCRPC, we Phase a September that
was in population. improvement With a months a survival XX.X months potential months, across median XX.X all this follow-up historical of median overall survival of the the cohorts, to median upon patient XX XX
investigation. a randomized and I dose dose from clinical schedule optimization data Phase Additional III for cohort the expansion and recommended identified Phase has
lines earlier therapy we Additionally, prostate in of in earlier stages in zalaridimig are of and studying combination cancer.
X of studies Recently, the we Ib ongoing. study I have combination additional enzalutamide with Phase Our localized in more investigating zalaridomag of in management initiated zalaritamig is abiraterone, and Phase upfront disease.
[indiscernible] therapy cancer. or prior evaluates to that diagnosed, first patients study neoadjuvant high-risk in intermediate newly prostate prostatectomy is The with localized, radical
The definitive in cancer prostate evaluates second hormone-sensitive high-risk after nonmetastatic therapy. study [indiscernible]
excited bispecific the development. particularly about zelaritamig, are third late-stage of engager We cell potential clinical our T entering now
Beyond bemarituzumab, factor gastric our with completed we chemotherapy in directed III our first-in-class IIb of XXX, fibroblast monoclonal nivolumab growth study T first-line of cancer. enrollment engagers, FORTITUDE combined cell have receptor a Phase antibody and
FOLFOXX survival. gastric to read out longer In results which in a the versus the study and study, FIGHT expect progression-free This chemotherapy overall designed FORTITUDE of coming first-line on XXX, successful reported months, II III of we study Phase chemotherapy bemarituzumab Phase cancer. based was combined alone survival numerically with the
PRMTX also recently with non-small oral Lastly, II rapidly cancer. NOL advanced Phase We September, dose previously from profile. XXX, we and MTAP tumors. solid a we in promising demonstrating inhibitor are treated I and cell NOL and AMG patients developed study our escalation advancing study In initial selection. a initiated dose XXX This expansion for lung of for AMG help encouraging activity monotherapy address study, presented safety Phase agency requirements an to acceptable optimization regulatory dose will data MTAP
per counts upon moderate greater Based These TEZSPIRE severe encouraging inflammation. with with collaboration COPD, target planning initiate COPD equal to Phase Phase trials patients cells blood data III eosinophil are in II microliter. Turning XXX with to patients AstraZeneca. or to studies we with to in very will from than
We expect of half to begin enrollment in first XXXX. the
studies expected in Phase also positive atopic polyps, line study from dermatitis. with secondary patients with Phase nasal study we later data TEZSPIRE in of endpoints III and September, in all where met In top Horizon The its eosinophilic this the separate is and chronic co-primary rocatinlumab key esophagitis results investigated are endpoints. announced being III year. of rinusetasitis
anticipate from deepen We understanding additional our data program of readouts the rocatinlumad's will ROCCAT profile.
on serious patients targeting of explore have Beyond as small [indiscernible] studies atopic systemic evidence suffering our CDXX we BLINCYTO Phase rheumatoid asthma inflammatory depletion blinatumomab more in benefit II as studies diseases rocatinlumab dermatitis, approved of nodularis. and aplisma. in and even autoimmune to mounting refractory for from CDXX continue To the arthritis. build investigator-sponsored severe of targeting therapeutic our CDXX expand of moderate sclerosis BiTE directed diseases, in for to prurigo These trials antibody approved therapeutics impact from we inebilizumab, initiated molecule and monoclonal B-cell our
on lupus will to focus initial Our be systemic with with arothematosis indications. plans nephritis into additional expand
generalized placebo-controlled populations. positive to rare autoantibody gravis. potentially a study, setlcholine autoantibody the a the MuSK-positive receptor Shifting largest in We Phase biologic trial positive ACHR disease. evaluated therapy practice-changing recently in and positive or presented UPLIZNA MINT results III MINT muscle-specific from myothenia kinase for both
population At clinically to ACHR MuSK-positive quantitative as observed improvements compared population myasthenia XX living This statistically compared myasthenia well in XX-week separately. and the placebo also score demonstrated significant UPLIZNA each UPLIZNA daily combined as activities combined doses week significant the X of and improvements efficacy the in the gravis the to statistically just reported time populations. was achieved in in at gravis point, score, meaningful after placebo. in
Importantly, to use. corticosteroids Phase and first at starting for taking corticosteroid placebo-controlled a per X-milligram week tapered Mint a myasthenia biologic by in MINT the were that III patients down gravis tapered the trial day week only XX. X is dose study,
without myasthenia aplisma the the and patients with generalized of with efficacy burden for a such, in steroid chance gravis chronic observed meaningful toxicity As offers benefit use.
cohort data has MINT open-label XX-week In to the ACHR and ACHR from UPLIZNA forward where period results populations. to study, and efficacy. patient of positive look the demonstrate durable the positive potential both for We MuSK-positive the
III upon Based in College generalized the UPLIZNA beyond for in diseases, November. data of August, treatment Phase designation the or Breakthrough the presented study. Conference Rheumatology This at myasthenia will GI-related data gravis American be of from Therapy disease. granted MITIGATE FDA Moving the IgGX-related immunoglobulin
both of in gravis and these regulatory the We and with disease UPLIZNA encouraged authorities. are working actively extremely to file by are IgGX-related myasthenia data potential
In commitment this closing, for their focus facing want to patients I grievous to for illnesses collaboration the Amgen the year. productive colleagues thank during my unwavering for
I'll to now update. turn financial the for it Peter over
